Author:
Martin Allison,Amin Janaki,Cooper David A,Carr Andrew,Kelleher Anthony D,Bloch Mark,Baker David,Woolley Ian,Emery Sean
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Immunology,Immunology and Allergy
Reference22 articles.
1. A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration.;Lancet,2008
2. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96 week trial;Martin;Clin Infect Dis,2009
3. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects;Brothers;J Acquir Immune Defic Syndr,2009
4. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected patients with virological suppression;Martinez;J Acquir Immune Defic Sydnr,2009
5. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients;Hsue;AIDS,2009
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献